NOV 17, 202658 MINS READ
Croscarmellose Sodium (also known as cross-linked sodium carboxymethylcellulose) is a chemically modified cellulose derivative characterized by internal cross-linking of carboxymethyl groups, yielding a three-dimensional polymeric network with exceptional water uptake capacity 1. The degree of substitution typically ranges from 0.60 to 0.85, which directly influences swelling volume and disintegration efficacy 3. Upon contact with aqueous media, the anionic carboxymethyl groups undergo rapid hydration and electrostatic repulsion, generating substantial swelling pressure (often exceeding 10–15 kPa within the first 30 seconds) that disrupts the tablet matrix from within 13.
When incorporated intragranularly, Croscarmellose Sodium is intimately dispersed within the granule structure during wet or dry granulation processes. This spatial distribution ensures that each granule contains disintegrant microdomains, which upon tablet compression and subsequent exposure to dissolution media, facilitate localized swelling and rapid granule breakdown 715. The intragranular positioning is particularly advantageous for hydrophobic or poorly water-soluble APIs, as it promotes immediate wicking of dissolution medium into the granule core, thereby accelerating drug particle deaggregation and surface area exposure 517.
Key physicochemical properties supporting intragranular functionality include:
Comparative studies demonstrate that intragranular Croscarmellose Sodium at 2–6% w/w achieves disintegration times 30–50% shorter than equivalent extragranular concentrations, attributed to the synergistic effect of internal swelling pressure and capillary water ingress 58.
The selection of Croscarmellose Sodium concentration in intragranular formulations is governed by API solubility, granule porosity, and target dissolution profile. Patent literature reveals that intragranular concentrations typically range from 0.75% to 6% w/w of total formulation weight, with higher levels (4–6%) reserved for poorly soluble drugs requiring aggressive disintegration 5814.
A dual-phase disintegrant strategy is frequently employed, wherein Croscarmellose Sodium is partitioned between intragranular and extragranular phases. For example, in a tamoxifen citrate formulation, 50% of the total Croscarmellose Sodium (approximately 1.5% w/w) was incorporated intragranularly, with the remainder added extragranularly to achieve >65% drug dissolution within 10 minutes in 0.02N HCl at 37°C 814. This split addition leverages intragranular disintegration for granule breakdown and extragranular disintegration for tablet-level fragmentation, yielding synergistic dissolution enhancement 8.
Critical formulation parameters include:
Croscarmellose Sodium intragranular addition is compatible with both wet and dry granulation techniques, though process-specific considerations apply.
Wet Granulation: In aqueous wet granulation, Croscarmellose Sodium is typically dry-blended with the API and diluent (e.g., microcrystalline cellulose, lactose, or mannitol) prior to liquid addition 38. The granulation liquid—commonly water or hydroalcoholic solutions (10–30% ethanol/70–90% water)—is sprayed incrementally to achieve a target granule moisture of 8–12% 1819. Binders such as polyvinylpyrrolidone (PVP) at 1–3% w/w or hydroxypropyl methylcellulose (HPMC) at 0.5–2% w/w are co-granulated to provide mechanical strength without impeding disintegration 1418. Post-granulation drying at 60–80°C in fluid-bed dryers reduces moisture to <2%, followed by milling through 1270 μm screens to achieve uniform granule size 89.
Dry Granulation (Roller Compaction): For moisture-sensitive APIs, Croscarmellose Sodium is blended with the drug and excipients, then compacted into ribbons at 5–15 kN/cm linear force 7. The ribbons are milled to 500–1000 μm granules, which are subsequently blended with extragranular excipients. Dry granulation minimizes exposure to water, preserving the disintegrant's swelling capacity and preventing API degradation 47.
Solvent-Based Granulation: A specialized method involves dispersing sodium carboxymethylcellulose (degree of substitution 0.8–0.9) in organic solvent/water mixtures (10:1 v/v, e.g., ethanol/water) at 40–50°C, followed by acidification with 15–30% sulfuric acid to pH 2–4 to induce self-cross-linking 3. This two-stage reaction (0.5–2 hours at 40–50°C, then 2–4 hours at 65–75°C) yields Croscarmellose Sodium with controlled cross-link density, which is then washed, dried at 70–90°C, and milled to 200 mesh 3. This approach offers precise control over swelling kinetics but requires careful pH and temperature management.
Excipient compatibility is generally excellent, though certain combinations require attention:
Disintegration time is the primary in-process control parameter, typically measured per USP <701> using a basket-rack assembly in 0.1N HCl or phosphate buffer pH 6.8 at 37 ± 0.5°C 117. Tablets containing intragranular Croscarmellose Sodium at 3–6% w/w routinely disintegrate within 2–5 minutes, compared to 8–15 minutes for formulations with extragranular-only addition 517.
Dissolution testing follows USP <711> Apparatus II (paddle method) at 50–100 rpm in 900–1000 mL of medium 28. For immediate-release formulations, the target is ≥80% drug release within 30 minutes (Q30 ≥ 80%) 817. High-performance liquid chromatography with charged aerosol detection (HPLC-CAD) enables quantification of Croscarmellose Sodium content in finished tablets, with typical recovery rates of 95–105% and RSD <3% 2. Sample preparation involves extracting the disintegrant with dilute acid, neutralizing, and injecting into a C18 column (e.g., 250 mm × 4.6 mm, 5 μm) with gradient elution (acetonitrile/water with 0.1% formic acid) 2.
Croscarmellose Sodium is hygroscopic, with equilibrium moisture content of 5–8% at 60% RH and 25°C 110. Intragranular formulations must be stored in moisture-barrier packaging (e.g., aluminum blisters or HDPE bottles with desiccant) to prevent moisture uptake, which can trigger premature swelling and loss of disintegration efficacy 10. Accelerated stability studies (40°C/75% RH for 6 months) should confirm <5% change in disintegration time and <10% change in dissolution profile 9.
A novel moisture-proof storage device for Croscarmellose Sodium employs a hot-air cavity with drying balls (silica gel or molecular sieves) to maintain <30% RH within the storage chamber, coupled with automated sealing mechanisms to minimize air ingress during material transfer 10. This system reduces moisture-related degradation by >60% compared to conventional storage 10.
Quantitative determination of Croscarmellose Sodium in tablets is achieved via HPLC-CAD, which detects all non-volatile substances without requiring chromophores 2. The method involves:
Microscopic imaging (scanning electron microscopy, SEM) of fractured tablets reveals the spatial distribution of Croscarmellose Sodium within granules, confirming uniform dispersion and absence of agglomeration 15. Energy-dispersive X-ray spectroscopy (EDX) mapping of sodium signals further validates intragranular localization 15.
A formulation comprising 5–15% w/w tamoxifen citrate utilized a split Croscarmellose Sodium strategy: 1.5% w/w intragranular (co-granulated with microcrystalline cellulose and lactose via aqueous wet granulation) and 1.5% w/w extragranular 8. The intragranular component was prepared by blending tamoxifen citrate, microcrystalline cellulose (10% w/w), lactose (65% w/w), Croscarmellose Sodium (1.5% w/w), and PVP (2% w/w), followed by granulation with water to 10% moisture, drying at 60°C, and milling to 850 μm 8. Extragranular addition of Croscarmellose Sodium (1.5% w/w), microcrystalline cellulose (5% w/w), and magnesium stearate (1% w/w) preceded compression at 8 kN 8.
Dissolution testing in 1000 mL of 0.02N HCl at 37°C (100 rpm) demonstrated 68 ± 4% drug release at 10 minutes and 92 ± 3% at 30 minutes, meeting bioequivalence criteria versus the reference product 8. The intragranular Croscarmellose Sodium contributed to rapid granule disintegration (<3 minutes), while the extragranular fraction ensured complete tablet fragmentation 8.
A dry granulation formulation containing 85–99% w/w ibuprofen incorporated 1–15% w/w Croscarmellose Sodium intragranularly to address the poor compressibility of the high-dose API 7. The process involved blending ibuprofen with Croscarmellose Sodium (6% w/w) and colloidal silicon dioxide (0.5% w/w), roller-compacting at 10 kN/cm, milling to 600 μm granules, and blending with extragranular magnesium stearate (0.8% w/w) 7. Tablets compressed at 12 kN exhibited disintegration times of 4.2 ± 0.6 minutes and Q30 of 88 ± 5%, significantly outperforming formulations with crospovidone (Q30 = 72%) or cornstarch (Q30 = 65%) at equivalent concentrations 7.
The intragranular Croscarmellose Sodium created a porous granule structure with 22% void fraction, facilitating rapid water ingress and ibuprofen particle dispersion 7. SEM imaging confirmed uniform disintegrant distribution and absence of API agglomeration 7.
A wet granulation formulation for eslicarbazepine acetate (80–90% w/w) employed a 50/50 split of Croscarmellose Sodium (total 3–10% w/w) between intragranular and extragranular phases 14. The intragranular component comprised eslicarbazepine acetate, PVP (3–10% w/w), and Croscarmellose Sodium (1.5–5% w/w), granulated with water, dried, and milled 14. Extragranular addition of Croscarmellose Sodium (1.5–5% w/w) and magnesium stearate (0.1–3% w/w) preceded compression 14.
This dual-phase strategy achieved controlled release with 30 ± 5% drug release at 2 hours, 60 ± 8% at 6 hours, and >85% at 12 hours in pH 6.8 phosphate buffer (75 rpm), meeting the target profile for once-daily dosing 14. The intragranular Croscarmellose Sodium provided initial burst release (facilitating rapid therapeutic onset), while the extragranular fraction sustained release through gradual tablet erosion 14.
Croscarmellose Sodium can serve as a taste-masking agent when applied as a coating to bitter APIs via fluidized-bed processing 6. Particles of the API (e.g., acetaminophen, ibuprofen) are suspended in a fluidized bed and sprayed with an aqueous Croscarmellose Sodium dispersion (10–20% w/w solids
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| ELI LILLY AND COMPANY | Immediate-release oncology tablets requiring rapid disintegration and enhanced dissolution for poorly soluble APIs in gastric environment. | Tamoxifen Citrate Tablets | Intragranular croscarmellose sodium (1.5% w/w) combined with extragranular addition achieves 68% drug release at 10 minutes and 92% at 30 minutes in 0.02N HCl, with tablet disintegration under 3 minutes, meeting bioequivalence criteria. |
| THE UPJOHN COMPANY | High-dose analgesic tablets (85-99% API) requiring enhanced compressibility and rapid dissolution in resource-limited dry granulation processes. | Ibuprofen High-Dose Tablets | Intragranular croscarmellose sodium (6% w/w) via dry granulation creates 22% void fraction porous granules, achieving 4.2-minute disintegration and 88% dissolution at 30 minutes, outperforming crospovidone and cornstarch formulations. |
| BIAL - Portela & Ca. S.A. | Extended-release neurological formulations requiring initial burst release for rapid therapeutic onset followed by sustained drug delivery over 12 hours. | Eslicarbazepine Acetate Extended-Release Tablets | Dual-phase croscarmellose sodium strategy (50% intragranular/50% extragranular, total 3-10% w/w) provides controlled release with 30% at 2 hours, 60% at 6 hours, and >85% at 12 hours, enabling once-daily dosing. |
| ORION CORPORATION | Immediate-release tablets for Parkinson's disease treatment requiring enhanced dissolution of poorly soluble catechol-based COMT inhibitors across physiological pH range. | Entacapone/Nitecapone Tablets | Croscarmellose sodium at 10-14% w/w concentration significantly increases release rate of catechol derivative APIs from oral compacted compositions, demonstrating superior disintegration performance compared to conventional 0.5-5% levels. |
| R.P. SCHERER TECHNOLOGIES INC. | Pediatric and geriatric oral solid dosage forms requiring taste masking of bitter APIs without compromising rapid disintegration and drug release profiles. | Taste-Masked Pharmaceutical Tablets | Croscarmellose sodium coating via fluidized-bed process masks bitter taste of APIs while preserving rapid tablet disintegration properties, combining organoleptic improvement with immediate-release functionality. |